A new anabolic compound, LLP2A-Ale, reserves periodontal bone loss in mice through augmentation of bone formation.

Min JiangLixian LiuRuiwu LiuKit S LamNancy E LaneWei Yao

Published in: BMC pharmacology & toxicology (2020)

Our findings indicated that LLP2A-Ale treatment rescued alveolar bone loss caused by PD, primarily by increasing bone formation. LLP2A-Ale also attenuated the circulating levels of a series of inflammatory cytokines and reversed the PD-induced suppression of systemic bone formation.

Keyphrases

bone loss
high glucose
diabetic rats
drug induced
type diabetes
combination therapy
replacement therapy